<DOC>
	<DOCNO>NCT01713621</DOCNO>
	<brief_summary>This study aim investigate concentration dependent effect OZ439 clearance P. falciparum parasites patient , specifically determination in-vivo minimum inhibitory concentration ( MIC ) OZ439 . Characterisation PK-PD ( Pharmacokinetic-Pharmacodynamic ) relationships essential rational evidence base dosing . The adaptive investigation range dose provide best chance accurate PK-PD characterisation , allow observation Plasmodium falciparum growth dynamic subsequent identification MIC MPC ( minimum parasiticidal concentration ) . Additionally tolerability pharmacokinetics OZ439 confirm . The PK/PD relationship OZ439 exposure subsequent effect parasitaemia investigate .</brief_summary>
	<brief_title>OZ439 PhIIa Study Plasmodium Falciparum : Extended Observation</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<criteria>1 . Male female patient age 18 60 year , inclusive 2 . Body weight 45 kg 90 kg inclusive 3 . Presence monoinfection P. falciparum confirm : 1 . Fever , define axillary temperature ≥ 37.5°C oral/rectal/tympanic temperature ≥ 38°C , history fever previous 24 hour ( history fever must document ) , 2 . Microscopically confirm parasite infection : 1,000 75,000 asexual parasite count/µL blood . 4 . Written informed consent , accordance local practice , provide patient . If patient unable write , witness consent permit accord local ethical consideration 5 . Ability swallow oral medication 6 . Ability willingness participate access health facility 7 . Agree hospitalization least 72h parasite fall level polymerase chain reaction ( PCR ) detection sign symptom malaria ; return daily study centre blood sample quantitative polymerase chain reaction ( qPCR ) , rehospitalisation qPCR level detectable . 1 . Patients sign symptom severe/complicated malaria require parenteral treatment accord World Health Organization Criteria 2010 2 . Mixed Plasmodium infection 3 . Severe vomiting , define three time 24 hour prior inclusion study inability tolerate oral treatment , severe diarrhoea define 3 watery stool per day 4 . Presence serious chronic clinical condition require hospitalization 5 . Severe malnutrition ( define weightforheight 3 standard deviation less 70 % median NCHS/WHO normalize reference value ) 6 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , QTc interval great equal 450 msec ) , respiratory ( include active tuberculosis ) , history jaundice , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric , history convulsion abnormality ( include head trauma ) 7 . Known history hypersensitivity , allergic adverse reaction artemisinin contain compound mefloquine 8 . Known active Hepatitis A Immunoglobulin M ( IgM ) ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) 9 . Have receive antimalarial treatment precede 14 day , determine history screen test 10 . Have receive antibacterial know antimalarial activity precede 14 day 11 . Have receive investigational drug within past 4 week 12 . Liver function test ( Aspartate Aminotransferase ( ASAT ) /Alanine Aminotransferase ( ALAT ) level ) &gt; 2x upper limit normal ( ULN ) Total Bilirubin normal &gt; 1.5xULN Total bilirubin &gt; 1 &gt; 1.5xULN 13 . Hemoglobin ( Hb ) level = &lt; 8g/dl 14 . Total Bilirubin &gt; 1.5XULN 15 . Serum creatinine level 2 time upper limit normal range ( &gt; 2xULN ) . 16 . Female patient must neither pregnant demonstrate negative serum pregnancy test screen urinary pregnancy test predose ( result predose assessment must confirm negative prior dose ) lactating , must willing take measure become pregnant study period safety followup period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>P. falciparum</keyword>
	<keyword>malaria</keyword>
</DOC>